SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors react to a new China aircraft order, though sentiment remains divided over whether the 200-jet deal meets market expectations. Community discussion is heavily focused on the stock's volatility and the potential for a long-term rebound driven by the company's massive backlog and the reopening of the Chinese market.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is rallying as a massive earnings beat and upward revenue guidance reinforce its status as a core infrastructure player in the AI semiconductor supercycle. The community is actively debating the company's long-term growth potential and durability of AI-driven capital expenditure, while traders closely monitor its role in enabling leading-edge logic, memory, and advanced packaging technologies.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station is rallying following a $100M strategic investment from the Winklevoss Capital Fund and better-than-expected quarterly earnings. Investors and the community are actively debating the stock's massive short squeeze potential, fueled by high short interest and renewed optimism regarding the broader crypto ecosystem's regulatory tailwinds.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is experiencing a significant surge as investors cheer reports that the U.S. government has approved the sale of advanced H200 AI chips to major Chinese tech firms, effectively reopening a key revenue channel. The community is actively debating the stock's massive market valuation and geopolitical implications, with many traders leaning into a bullish momentum play leading up to next week's earnings.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors weigh the impending acquisition of Northern Data and its significant AI infrastructure assets against an upcoming earnings release. The community remains highly focused on the potential for a short squeeze, driven by high short interest and the company's shift toward becoming a sovereign AI and cloud compute powerhouse.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending following a strong quarterly earnings report featuring revenue growth that beat analyst expectations and raised full-year guidance, fueled by accelerating enterprise adoption of its AI-powered features. Community sentiment is heavily focused on a potential short squeeze, with investors highlighting significant short interest and arguing that the companys strong net dollar retention and essential role in design workflows prove its long-term value despite broader market concerns about AI competition.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is trending as investors anticipate key clinical presentations at the upcoming ATS International Conference, with community discourse heavily focused on potential M&A activity and the impact of recent institutional accumulation on a tight float. Discussion is centered on the company's Phase 3 data for paridiprubart and speculation regarding strategic partnerships or buyouts amid high short-interest dynamics.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is seeing heightened community discussion as investors weigh the stock's recent reimbursement J-code catalyst against frustration over management's limited public communication. Shareholders are closely monitoring the commercial rollout of Yartemlea and upcoming EMA approval milestones, while debating the impact of aggressive short interest on current price action.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.

Elicio Therapeutics Inc.

Elicio Therapeutics Inc

Elicio Therapeutics is trending as investors focus on the company's proprietary AMP technology and upcoming data readouts for its lead cancer vaccine candidate, ELI-002, which targets KRAS-driven tumors. The community is actively debating the company's long-term potential as an acquisition target versus the risks associated with the clinical-stage biotech's capital requirements and the potential for future share dilution.

Mobia Medical, Inc. operates as a commercial-stage medical device company. It engages in developing solutions for stroke recovery survivors with motor impairments. The company was founded by Lawrence James Cauller, Navzer Engineer, Thomas Jordan Curnes II, and William Michael Rosellini on March 5, 2007 and is headquartered in Austin, TX.

Mobia Medical Inc.

Sky-mobi Limited

Sky-mobi is gaining traction as investors discuss its low float and potential for a breakout, with many in the community focusing on the company's financial turnaround and future earnings. Traders are actively debating whether the stock is a prime candidate for a short squeeze or a long-term play, while keeping a close eye on the lack of institutional ownership and the impact of the newly appointed CFO.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Royal Bank Of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock Price

Royal Bank Of Canada raised their price target on shares of Pacira BioSciences from $22.00 to $24.00 and gave the company a "sector perform" rating in a research report on Friday...

Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.

Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up Following Analyst Upgrade

Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up After Analyst Upgrade...

Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release

Key PointsCFO Shawn Cross exercised and sold 12,941 shares on April 23, 2026, for a transaction value of ~$326,000 at around $25.16 per share...

Needham & Company LLC Raises Pacira BioSciences (NASDAQ:PCRX) Price Target to $32.00

Needham & Company LLC boosted their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Friday...

Pacira BioSciences (NASDAQ:PCRX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by...

Pacira BioSciences Q1 Earnings Call Highlights

Pacira BioSciences (NASDAQ:PCRX) reported first-quarter 2026 results that management said reflect continued momentum under its 5x30 strategy, highlighted by year-over-year growth across its three...

Pacira (PCRX) Q1 Earnings Miss Estimates

Pacira (PCRX) delivered earnings and revenue surprises of -1.64% and +0.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Pacira BioSciences Q1 2026 Earnings Call Transcript

Do Options Traders Know Something About Pacira BioSciences Stock We Don't?

Investors need to pay close attention to PCRX stock based on the movements in the options market lately.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Current Price	$23.53
Prev Close	$23.04
Open	$23.14
Dividend Yield	0.00%
50-Day Moving Average	$23.51
Beta	0.32
Avg. Volume	515,202.12
PE Ratio	188.39

52-Week High	$27.64
52-Week Low	$18.80
Market Capitalization	$906.28M
EPS (Annual)	$0.1562
Price to Book	1.41
Revenue Per Employee	$876,249.70

PCRX
Pacira BioSciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PCRX News

PCRXPacira BioSciences Inc